Spanish oncologist Mariano Barbacid's team achieved complete elimination of KRAS-mutated pancreatic tumors in mice using a low-toxicity trio of drugs (gemcitabine, ATRA, and neratinib), as detailed in a January 27, 2026, PNAS study.